Mark J. Mulligan, M.D.

Director
NYU Grossman School of Medicine
New York, New York, United States

Disclosure(s): HilleVax: Advisor/Consultant; Meissa Vaccines: Advisor/Consultant; Pfizer: Advisor/Consultant, Grant/Research Support; Sanofi: Grant/Research Support

Presentation(s):

• 229 - IDSA FEATURED ORAL ABSTRACT: MVA-BN Induces a Low Avidity, Non-Durable Humoral Response Against Mpox Virus

  Thursday, October 17, 2024
  5:05 PM – 5:20 PM US PT